Vansteenkiste, J., Fehrenbacher, L., Spira, A., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., Braiteh, F., Yi, J., He, P., Kowanetz, M., Waterkamp, D., Ballinger, M., Chen, D., Sandler, A., & Rittmeyer, A. (n.d.). 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). European journal of cancer, 51(3), S716–S717. http://access.bl.uk/ark:/81055/vdc_100050955402.0x00003b